TY - JOUR
T1 - Atypical parkinsonian syndromes
T2 - a general neurologist's perspective
AU - Deutschländer, A. B.
AU - Ross, O. A.
AU - Dickson, D. W.
AU - Wszolek, Z. K.
N1 - Funding Information:
AD is supported by the Max Kade Foundation and a Gift from Carl Edward Bolch, Jr, and Susan Bass Bolch. ZKW is partially supported by the NIH/ NINDS P50 NS072187, Mayo Clinic Neuroscience Focused Research Team (Cecilia and Dan Carmichael Family Foundation and the James C. and Sarah K. Kennedy Fund for Neurodegenerative Disease Research at the Mayo Clinic in Florida), the Sol Goldman Charitable Trust and a Gift from Donald G. and Jodi P. Heeringa. OAR is supported by the Morris K. Udall Parkinson’s Disease Research Center of Excellence (P50-NS072187), R01-NS078086 and U54-NS10069 and the Mayo Clinic Neuroscience Focused Research Team.
Publisher Copyright:
© 2017 EAN
PY - 2018/1
Y1 - 2018/1
N2 - The differential diagnosis of atypical parkinsonian syndromes is challenging. These severe and often rapidly progressive neurodegenerative disorders are clinically heterogeneous and show significant phenotypic overlap. Here, clinical, imaging, neuropathological and genetic features of multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and frontotemporal lobar degeneration (FTLD) are reviewed. The terms corticobasal degeneration and FTLD refer to pathologically confirmed cases of corticobasal syndrome and frontotemporal dementia (FTD). Frontotemporal lobar degeneration clinically presents as the behavioral variant FTD, semantic variant primary progressive aphasia (PPA), non-fluent agrammatic variant PPA, logopenic variant PPA and FTD associated with motor neuron disease. While progressive supranuclear palsy and corticobasal syndrome have been called Parkinson-plus syndromes in the past, they are now classified as FTD-related disorders, reflecting that they pathologically differ from α-synucleinopathies like multiple system atrophy and Parkinson disease. The contribution of genetic factors to atypical parkinsonian syndromes is increasingly recognized. Genes involved in the etiology of FTLD include MAPT, GRN and C9orf72. Novel neuroimaging techniques, including tau positron emission tomography imaging, are being investigated. Multimodal magnetic resonance imaging approaches and automated magnetic resonance imaging volume segmentation techniques are being evaluated for optimized differential diagnosis. Current treatment options are symptomatic, and disease modifying therapies are under active investigation.
AB - The differential diagnosis of atypical parkinsonian syndromes is challenging. These severe and often rapidly progressive neurodegenerative disorders are clinically heterogeneous and show significant phenotypic overlap. Here, clinical, imaging, neuropathological and genetic features of multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and frontotemporal lobar degeneration (FTLD) are reviewed. The terms corticobasal degeneration and FTLD refer to pathologically confirmed cases of corticobasal syndrome and frontotemporal dementia (FTD). Frontotemporal lobar degeneration clinically presents as the behavioral variant FTD, semantic variant primary progressive aphasia (PPA), non-fluent agrammatic variant PPA, logopenic variant PPA and FTD associated with motor neuron disease. While progressive supranuclear palsy and corticobasal syndrome have been called Parkinson-plus syndromes in the past, they are now classified as FTD-related disorders, reflecting that they pathologically differ from α-synucleinopathies like multiple system atrophy and Parkinson disease. The contribution of genetic factors to atypical parkinsonian syndromes is increasingly recognized. Genes involved in the etiology of FTLD include MAPT, GRN and C9orf72. Novel neuroimaging techniques, including tau positron emission tomography imaging, are being investigated. Multimodal magnetic resonance imaging approaches and automated magnetic resonance imaging volume segmentation techniques are being evaluated for optimized differential diagnosis. Current treatment options are symptomatic, and disease modifying therapies are under active investigation.
KW - corticobasal syndrome
KW - frontotemporal dementia
KW - multiple system atrophy
KW - primary progressive aphasia
KW - progressive supranuclear palsy
KW - tauopathy
KW - α-synucleinopathy
UR - http://www.scopus.com/inward/record.url?scp=85038896130&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038896130&partnerID=8YFLogxK
U2 - 10.1111/ene.13412
DO - 10.1111/ene.13412
M3 - Review article
C2 - 28803444
AN - SCOPUS:85038896130
SN - 1351-5101
VL - 25
SP - 41
EP - 58
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 1
ER -